Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has reported that the Federal Court of Appeal of Canada has reversed a lower court ruling which held that Pfizer's enantiomer patent could not block generic manufacturer Ranbaxy Laboratories from obtaining approval for a competitor product to Lipitor.
Subscribe to our email newsletter
The appellate court issued an order prohibiting regulatory approval of Ranbaxy’s product in Canada until Pfizer’s enantiomer (calcium salt) patent expires in July 2010. Ranbaxy may seek a review of the decision by the Supreme Court of Canada.
Peter Richardson, senior vice president of Pfizer, said: “This decision sends a strong signal about the importance of protecting intellectual property in Canada, which provides the incentive for research-driven pharmaceutical companies to make the significant high-risk investments necessary to develop new life-saving medicines.”